Apomorphine

CAT: 0804-HY-12723-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-12723-01Size:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Apomorphine is an orally active agonist of Dopamine receptor. Apomorphine can be used in study Parkinson, biphasic dyskinesias, urinary dysfunction, , dystonia, dyspnoea, anismus and belching[1].
CAS Number
[58-00-4]
Product Name Alternative
(-) -Apomorphine
UNSPSC
12352005
Hazard Statement
H302, H312, H332
Target
5-HT Receptor; Dopamine Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/apomorphine.html
Purity
99.48
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
OC1=CC=C2C(C3=C4C(CCN(C)[C@]4([H])C2)=CC=C3)=C1O
Molecular Formula
C17H17NO2
Molecular Weight
267.32
Precautions
H302, H312, H332
References & Citations
[1]Frankel JP, et al. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1990 Feb;53 (2) :96-101.|[2]Carbone F, et al. Apomorphine for Parkinson's Disease: Efficacy and Safety of Current and New Formulations. CNS Drugs. 2019 Sep;33 (9) :905-918.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Launched
Citation 01
Funct Integr Genomics. 2024 Sep 17;24 (5) :161.|Genes. 2025 Jun 29;16 (7) :768.|NPJ Parkinsons Dis. 2025 Nov 28;11 (1) :342.|Acta Pharmacol Sin. 2025 May 6.|Sci Rep. 2019 Jan 22;9 (1) :254. |Andrologia. 2019 Feb;51 (1) :e13160.|Andrology. 2022 May;10 (4) :808-817.|Asian J Androl. 2018 Sep-Oct;20 (5) :448-453.|J Sex Med. 2018 Feb;15 (2) :136-147. |Oxid Med Cell Longev. 2018 Jun 26:2018:2917981.

Related Products

CatalogName

Popular Products